Product Description
Mechanisms of Action: mTOR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Soft Tissue Cancer|Bone Cancer|Sarcoma|Osteosarcoma
Phase 2: Sarcoma|Breast Cancer|Endometrial Cancer|Prostate Cancer|Oncology Unspecified|Leiomyosarcoma|Osteosarcoma|Non-Small-Cell Lung Cancer|Liposarcoma|Myeloid Leukemia|Myelodysplastic Syndrome|Lymphoma|Myelofibrosis
Phase 1: Lymphoma|Non-Small-Cell Lung Cancer|Sarcoma|Ovarian Cancer|Glioma|Glioblastoma|Gliosarcoma|Oncology Solid Tumor Unspecified|Heart Cancer|Oncology Unspecified|Multiple Myeloma|Endometrial Cancer|Prostate Cancer|Breast Cancer|Peritoneal Cancer|Hepatic Insufficiency|Fallopian Tube Cancer|Primary Central Nervous System Lymphoma|Liver Failure|Colorectal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
IoNIR-002 | N/A |
Not yet recruiting |
Coronary Artery Disease|Coronary Stenosis |
2026-09-01 |
|
CHAMPIONSHIP | N/A |
Recruiting |
Peripheral Arterial Disease |
2025-08-30 |
|
IonMAN | N/A |
Active, not recruiting |
Non-ST Elevated Myocardial Infarction|Coronary Disease|Coronary Stenosis |
2024-09-30 |
|
EluNIR-005 | N/A |
Completed |
Coronary Stenosis|Myocardial Ischemia |
2021-11-02 |